Physician profile
Kenneth E Izuora
NPI 1023167525
$5,879.11
in general payments reported to CMS, 2019-2025
37 companies · $821 in 2025
The $821 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $950 · 2020: $262 · 2021: $537 · 2022: $892 · 2023: $1,394 · 2024: $1,024 · 2025: $821.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,238.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $625.30 | 2019-2023 | |
| Amgen INC. | $625.15 | 2019-2024 | Evenity, Repatha, Prolia |
| Novo Nordisk INC | $523.51 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $377.24 | 2019-2023 | Korlym |
| Insulet Corporation | $298.92 | 2021-2023 | Omnipod |
| Medtronic, INC. | $223.04 | 2023-2024 | Minimed 780g |
| Xeris Pharmaceuticals, INC. | $210.62 | 2023-2024 | Recorlev |
| Horizon Therapeutics Plc | $197.50 | 2022-2023 | Tepezza |
| Amryt Pharma Holdings LTD | $181.07 | 2022-2023 | Mycapssa |
| Abbott Laboratories | $178.85 | 2021-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.20 | 2023-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $140.92 | 2020-2023 | |
| Abbvie INC. | $139.17 | 2019-2024 | |
| Neurocrine Biosciences, INC. | $138.35 | 2025 | |
| Ascendis Pharma Endocrinology INC | $125.25 | 2025 | Yorvipath |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $124.99 | 2024 | Resmetirom |
| Chiesi USA, INC. | $124.97 | 2024 | Mycapssa |
| Gilead Sciences, INC. | $123.70 | 2019 | |
| Averitas Pharma INC. | $118.74 | 2025 | Qutenza |
| Ipsen Biopharmaceuticals, INC | $116.81 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $115.94 | 2023 | |
| Tandem Diabetes Care, INC. | $113.88 | 2020 | |
| Alexion Pharmaceuticals, INC. | $113.43 | 2019-2024 | Strensiq |
| Merck Sharp & Dohme LLC | $109.38 | 2019 | |
| Esperion Therapeutics, INC. | $109.18 | 2024 | Nexletol |
| Radius Health, INC. | $95.04 | 2023-2025 | Tymlos |
| Dexcom, INC. | $76.82 | 2021-2025 | Dexcom G6 Transmitter |
| Ucb, INC. | $76.75 | 2021-2023 | Briviact |
| Lilly USA, LLC | $69.51 | 2020-2023 | Baqsimi, Jardiance |
| Recordati_rare_diseases_inc. | $46.24 | 2024 | Signifor Lar, Isturisa |
| Mannkind Corporation | $41.56 | 2022-2025 | |
| Sarepta Therapeutics, INC. | $29.00 | 2023 | Exondys 51 |
| Soleno Therapeutics, INC. | $27.20 | 2025 | Vykat Xr |
| Pfizer INC. | $24.39 | 2022 | |
| Ibsa Pharma INC. | $23.93 | 2023 | Tirosint, Licart |
| Lundbeck LLC | $23.11 | 2025 | Vyepti |
| Kyowa Kirin, INC. | $20.45 | 2023 | Crysvita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Izuora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.